Related Experiment Video
Updated: Jun 6, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Are we ready to use aliskiren in children?
Erin Elizabeth Kelland1, Leanne Michelle McAuley, Guido Filler
1Department of Pediatrics, Children's Hospital, London Health Sciences Centre, University of Western Ontario, 800 Commissioners Road East, London, N6A 5W9, ON, Canada.
Abstract:
The objective of this case series was to review the safety and efficacy of aliskiren in combination with losartan in pediatric chronic kidney disease (CKD) patients. This was a retrospective study in which the medical files of all patients who had received aliskiren were reviewed. Four patients were identified between 5 and 18 years of age who had received aliskiren and losartan for the reduction of refractory proteinuria. While proteinuria was reduced in all four of these patients by 45, 96, 53, and 64%, respectively, three patients experienced side effects requiring changes in the aliskiren dose. A significant side effect occurred in the patient with CKD stage 3 who suffered accelerated loss of kidney function leading to dialysis after only a short course of therapy. The data from this preliminary trial strongly suggest that clinicians should exercise caution when prescribing aliskiren in combination with losartan until appropriate pediatric trials establish dosing, efficacy, and safety.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Antihypertensive Drugs: Direct Renin Inhibitors
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Drug Dosing: Infants and Children
Pharmacokinetics in Pediatric Patients: Drug Distribution
Acute Kidney Injury I: Introduction